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Abstract 
Aim: Preoperative fluid and electrolyte management is usually performed by intravenous 
therapy. We investigated the safety and effectiveness of oral rehydration therapy (ORT) for 
preoperative fluid and electrolyte management of surgical patients. 
Methods: The study consisted of two studies, designed as a prospective observational study. 
In a pilot study, 20 surgical patients consumed 1000 mL of an oral rehydration solution (ORS) 
until 2 h before induction of general anesthesia. Parameters such as serum electrolyte con-
centrations, fractional excretion of sodium (FENa) as an index of renal blood flow, volume of 
esophageal-pharyngeal fluid and gastric fluid (EPGF), and patient satisfaction with ORT were 
assessed. In a follow-up study to assess the safety of ORT, 1078 surgical patients, who con-
sumed ORS until 2 h before induction of general anesthesia, were assessed. 
Results: In the pilot study, water, electrolytes, and carbohydrate were effectively and safely 
supplied by ORT. The FENa value was increased at 2 h following ORT. The volume of EPGF 
collected following the induction of anesthesia was 5.3±5.6 mL. In the follow-up study, a small 
amount of vomiting occurred in one patient, and no aspiration occurred in the patients. 
Conclusion: These results suggest that ORT is a safe and effective therapy for the pre-
operative fluid and electrolyte management of selected surgical patients. 
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Introduction 
Preoperative  fasting  beginning  the  day  before 
surgery has been standard practice to prevent aspira-
tion  pneumonia  associated  with  general  anesthesia 
[1];  thus  before  surgery,  the  patients  are  inevitably 
exposed  to  dry  month  and  hunger.  In  Japan,  pre-
operative fluid and electrolyte management is usually 
performed  by  intravenous  therapy,  and  the  fasting 
time prior to surgery seems to be longer than in other 
countries  [2].  However,  due  to  a  lack  of  sufficient 
scientific  evidence  [1],  the  period  of  preoperative 
fasting has recently been reevaluated, and societies of 
anesthesiology in the United States and most Euro-
pean  countries  have  revised  the  practice  guidelines 
for preoperative fasting so that the oral intake of clear 
fluids may be permissible up to 23 h before surgery 
in selected surgical patients (excluding those in whom 
delayed  gastric  emptying  is  suspected)  [3]. In  addi-
tion,  an  approach  for  minimizing  surgery-related 
stress  and  reducing  subsequent  complications  has 
been  introduced  by  Fearon  et  al.  as  the  “enhanced 
recovery after surgery” (ERAS) protocol, addressing 
the  disadvantage  of  preoperative  fasting  [4].  As  re-
ported by Nygren et al., preoperative oral provision of 
carbohydrates and fluids helps to alleviate anxiety of 
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patients and also reduces the dry mouth and feeling 
of  hunger  caused  by  preoperative  fasting  [5].  Also, 
carbohydrate  loading  before  surgery  helps  reduce 
postoperative insulin resistance [6]. In April 2007, our 
institution began using an oral rehydration solution 
(ORS) as the clear fluid for oral rehydration therapy 
(ORT) [7]. The ORS is one of the selections for dehy-
dration treatment recommended by the World Health 
Organization  (WHO)  to  supply  water,  electrolytes, 
and  carbohydrates  as  comparable  to  intravenous 
therapy [8−10] and has recently  gained  widespread 
acceptance and is now preferred in the United States 
and in European countries. In the pilot study, we in-
vestigated the safety and effectiveness of ORT for the 
preoperative  fluid  and  electrolyte  management  of 
patients  receiving  general  anesthesia  before  breast 
surgery, and in the follow-up study on the safety of 
ORT, we assessed the safety of ORT in 1078 surgical 
patients  who  were  treated  with  ORT  during  the12 
months after the pilot study. 
Methods 
The study, designed as a prospective observation 
study,  was  approved  by  the  institutional  review 
board  of  the  study  institution  (Kanagawa  Cancer 
Center, Japan) and was conducted in accordance with 
the  Declaration  of  Helsinki.  Voluntary  written  in-
formed  consent  was  obtained  from  all  subjects  en-
rolled in the study. 
In  a  pilot  study,  20  patients  who  underwent 
breast  surgery  were  enrolled  in  the  study.  The  pa-
tients were those with physical status classification I 
or  II  of  the  American  Society  of  Anesthesiologists 
(ASA),  who  were  scheduled  to  enter  the  operating 
room at 13:00 for breast surgery. Patients who were 
unable to take food by mouth, patients who had pre-
viously  received  gastroesophageal  surgery,  patients 
with a body weight of 40 kg or less or 70 kg or more, 
patients  with  reduced  creatinine  clearance  (80 
mL/min or less), and patients with abnormal glucose 
tolerance (fasting blood glucose level, 120 mg/dL or 
more) were excluded from the study. The ORS con-
taining water, glucose, and electrolytes, packaged in a 
500-mL  plastic  bottle  (OS-1,  classified  as  a  food  in 
Japan,  Otsuka  Pharmaceutical  Factory,  Inc.,  To-
kushima, Japan), was used in the study. Its composi-
tion is shown in Table 1. Patients consumed a stand-
ard diet at 18:00 on the day before surgery and fasted 
thereafter (with water permitted until 24:00). On the 
day of surgery, the patients drank 1000 mL of the ORS 
from a bottle from 8:00 to 11:00 at a volume of 333 
mL/h.  The  patients  were  not  premedicated  and 
walked into the operating room at 13:00. Then, anes-
thesia was induced with propofol (1.5 mg/kg), fen-
tanyl citrate (2 /kg), and vecuronium bromide (0.1 
mg/kg);  a  laryngeal  mask  (Proseal  #3,  Laryngeal 
Mask Company, Henley-on-Thames, UK) was used to 
secure the airway. After the airway was secured, sys-
temic anesthesia was maintained with propofol at 4 
mg/kg  per  h.  Blood,  urine,  and  esophage-
al-pharyngeal fluid and gastric fluid (EPGF) samples 
were obtained within 3 min after the induction of an-
esthesia, and the volume of intravenous solution ad-
ministered during that period was less than 10 mL. To 
sample EPGF, after induction of anesthesia, a gastric 
tube (14 Fr, Termo Co., Ltd., Tokyo, Japan) was in-
serted 75 cm from the tip of the drain tube of the lar-
yngeal  mask  to  sample  EPGF.  The  tube  was  then 
pulled back to 45 cm from the tip of the drain tube 
while fluid was aspirated with a 50-mL catheter sy-
ringe  GA  (Nipro  Corporation,  Tokyo,  Japan)  under 
negative pressure in a face-up position. This proce-
dure was repeated three times, and the gastric tube 
was  then  pulled  back  into  the  pharynx  to  sample 
EPGF. Sampling of EPGF was conducted by the same 
person. 
 
Table 1. Composition of oral rehydration solution 
  Oral rehydration solution (OS-1) 
Volume (mL)  500 
Energy (kcal) 
Carbohydrate (%) 
50 
2.5 (glucose 1.8) 
Electrolytes (mEq/L)   
Sodium (Na+)  50 
Potassium (K+)  20 
Magnesium (Mg2+)  2 
Lactate–  31 
Chloride (Cl–)  50 
Phosphorus (mmol/L)  2 
pH  3.9 
Osmolarity  Approx. 270 mOsm/L 
 
 
With regard to the safety  of ORT, the rates of 
occurrence of vomiting and aspiration at the time of 
induction of anesthesia were investigated (in 20 pa-
tients). Volumes of EPGF obtained following induc-
tion  of  anesthesia  were  measured.  Vital  signs  were 
measured before and at 1 and 2 h after ingestion of the 
ORS was completed. Blood pressure and pulse rate 
were measured at the right upper arm bound with a 
cuff by a bed-side monitor (BSM-2301, Nihon Koden 
Corporation,  Tokyo,  Japan).  Body  temperature  was 
measured  at  the  right  axilla  by  an  electronic  ther-
mometer  (ET-C202P01,  Termo  Corporation,  Tokyo, 
Japan). Int. J. Med. Sci. 2011, 8 
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With regard to the efficacy of ORT, the changes 
in  serum  electrolyte  (sodium,  potassium,  and  chlo-
ride), glucose, and hematocrit values following rehy-
dration with the ORS was evaluated before and 2 h 
after the end of ORS consumption. The samples were 
analyzed immediately after they were obtained. The 
electrolyte concentrations in blood, urine, and EPGF 
as  well  as  serum  glucose  were  measured  using  an 
automatic  analyzer  (Hitachi  7170S,  Hitachi 
High-Technologies Corporation, Tokyo, Japan); blood 
cell counts were determined using an automatic blood 
cell analyzer (Sysmex XE-2100, Sysmex TMC, Kobe, 
Japan); and pH values were measured with a pH me-
ter  (B-211,  Horiba,  Ltd.,  Kyoto,  Japan).  To  estimate 
renal blood flow, the fractional excretion of sodium 
(FENa) and the change in FENa (∆FENa) following 
rehydration were evaluated. The FENa was calculated 
by  the  following  equation;  FENa=  (urinary  sodium 
concentration  serum creatinine value/serum sodi-
um concentration  urinary creatinine value)  100. 
With regard to the assessment of patient satis-
faction,  the  incidence  rates  of  feeling  hunger,  dry 
mouth, and a feeling of restriction, which were de-
termined by using a questionnaire, were investigated 
to assess the patients’ satisfaction with the treatment. 
Descriptive  statistics  (the  number  of  patients, 
mean value, standard deviation, maximum value, top 
quartile,  median  value,  bottom  quartile,  and  mini-
mum  value)  were  obtained  for  serum  electrolytes 
(sodium,  potassium,  and  chloride),  serum  glucose, 
serum creatinine, hematocrit, vital signs, preoperative 
urine volume, urinary sodium, and urinary creatinine. 
Vital  signs  were  analyzed  using  the  repeat-
ed-measures analysis of variance and the Dunnett test 
(two-sided  at  =0.05).  Blood  and  urine  values  and 
FENa  values  before  and  after  treatment  were  ana-
lyzed  for  differences  using  the  t-test  (two-sided  at 
=0.05). 
In  the  follow-up  study  to  assess  the  safety  of 
ORT, 1078 surgical patients who received ORT before 
induction  of  general  anesthesia  during  12  months 
(August  2007  to  August  2008)  after  the  pilot  study 
were assessed. The patients were those with physical 
status classification I or II of American Society of An-
esthesiologists  (ASA)  who  were  judged  appropriate 
for  ORT  by  the  attending  physician  and  agreed  to 
receive the ORT. Inclusion and exclusion criteria were 
the same as in the pilot study. The patients, who did 
not  agree  to  receive  the  ORT,  received  intravenous 
therapy instead. The oral rehydration solution given 
to the patients was the same as that used in the pilot 
study. Following a meal and after 19:00 on the day 
before surgery, the patients were given three bottles 
of the study solution (500 mL  3 bottles) and allowed 
to freely consume the solution until 2 h before enter-
ing  the  operating room for surgery,  same as in the 
pilot  study,  but  were  instructed  not  to  consume  a 
large  volume  at  a  time  (consume  in  a  divided  vol-
ume). The largest volume of consumption was set to 
be 1500 mL and the patients, if unable to consume at 
least 500 mL, received intravenous therapy. For pa-
tients  with  malignant  gastric  cancer,  the  timing  of 
consumption was limited to up to 6 h before surgery 
because of the possibility of delayed gastric emptying. 
Bowel  preparation  such  as  using  laxatives  was  not 
restricted during the study period. The patients were 
not  premedicated  and  walked  into  the  operating 
room. The method of anesthesia was not specified. For 
the safety assessment, the occurrence rates of vomit-
ing and aspiration at the time of induction of anes-
thesia were investigated to assess the adverse events 
and  adverse  reactions  associated  with  the  therapy. 
Vomiting  was  defined  as  the  reflux  of  gastric  or 
esophageal content to oral cavity at the time of anes-
thesia induction. Aspiration was defined as the case in 
which  the  contents  of  vomiting  are  identical  to  the 
tracheal contents aspirated through endotracheal in-
tubation. 
Results 
Pilot study: Twenty patients were registered in 
the study. Their baseline characteristics are shown in 
Table 2. Creatinine clearance value, measured as an 
index  of  renal  function,  was  99.918.4  mL/min 
(n=20). Vomiting and aspiration associated with the 
induction  of  general  anesthesia  were  not  observed. 
The volume of EPGF collected following induction of 
anesthesia was 5.3±5.6 mL (0.1±0.1 mL/kg). With re-
gard to vital signs, blood pressure (diastolic), pulse 
rate,  and  body  temperature  were  not  changed  fol-
lowing treatment. Systolic blood pressure showed an 
increase  at  2  h  after  treatment  (before  anesthesia) 
(126±22 mmHg vs. 137±20 mmHg, P0.001) (Figure 1). 
With ORT, no changes were observed in the serum 
concentrations  of  potassium  and  chloride  and  the 
hematocrit  value  (Figure  2).  In  contrast,  the  serum 
concentration  of  sodium  was  decreased  within  the 
normal limits (sodium: 135–147 mEq/l) established at 
the study institution, and no changes were observed 
in the urinary sodium concentrations. The blood glu-
cose was increased within the normal limits (70110 
mg/dL) (Figure 2). FENa was increased at 2 hr fol-
lowing  ORT  (0.54±0.36  vs.  0.76±0.48,  p=0.006),  and 
FENa showed a positive value (0.22±0.32) (Figure 3). 
The  results  of  the  questionnaire  survey  on  patient 
satisfaction with the ORT are shown in Figure 4. Most 
of the patients (95%) replied that they would prefer 
ORT the next time. Int. J. Med. Sci. 2011, 8 
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Table 2. Baseline characteristics of patients in the pilot study 
    Number of patients  % 
Patients    20 women   
Age (years)  20−39  3  15.0 
  40−59  11  55.0 
  60−79  6  30.0 
  80 or more  0  0.0 
Body weight (kg)  Less than 50  4  20.0 
  50−59  11  55.0 
  60−69  5  25.0 
  70−79  0  0.0 
  80 or more  0  0.0 
Height (cm)  Less than 150  2  10.0 
  150−159  14  70.0 
  160−169  4  20.0 
  170 or more  0  0.0 
Diagnosis  Breast cancer  20  100 
  Other  0  0 
ASA physical status classification  ASA I  16  80.0 
  ASA II  4  20.0 
Complications and past history  None  15  75.0 
  Present  5  25.0 
ASA: American Society of Anesthesiologists. 
 
 
 
Figure 1. Changes in blood pressure, pulse rate, and body temperature. ORT: oral rehydration therapy. Values at each 
measurement time point were analyzed for changes over time by repeated measures analysis of variance (=0.05). If dif-
ferences from baseline value (i.e., changes over time) were significant, changes from the baseline value were analyzed by the 
Dunnett test (=0.05). Systolic blood pressure showed an increase at 2 h after treatment (before anesthesia) (P0.001). Int. J. Med. Sci. 2011, 8 
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Figure 2. Serum electrolyte (sodium, potassium, and chloride), urinary sodium, hematocrit, and serum glucose values. 
ORT: oral rehydration therapy. Values were analyzed by the t-test (=0.05). Following treatment, serum sodium level was 
decreased within the normal ranges specified at the study hospital (P=0.008) and the glucose level was increased (P0.001). 
 
 
Figure 3. Fractional excretion of sodium (FENa) and the change in FENa (∆FENa) following rehydration (ORT). FENa= 
(urinary sodium concentration  serum creatinine value/serum sodium concentration  urinary creatinine value)  100. 
∆FENa: change in FENa following rehydration. Values were analyzed by the t-test. FENa was increased at 2 h following 
rehydration (P=0.006) and ∆FENa was positive. Int. J. Med. Sci. 2011, 8 
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Figure 4. Patient satisfaction (Q&A) with the therapy (ORT). 
 
 
 
 
Follow-up study: A total of 1078 patients who 
received ORT before surgery during 12 months after 
the pilot study were evaluated. Primary diseases of 
these  patients  are  shown  in  Table  3.  Neurosurgical 
and colon surgery patients were not included in the 
study because the consents for patient enrolment in 
the  study  were  not  obtained  from  their  attending 
physicians  (because  there  are  risks  of  a  decrease  in 
conscious  level,  paralysis,  and  an  increase  in  intra-
cranial pressure in neurosurgical patients as well as 
risks  of  preoperative  reduction  of  intragastric  tube 
pressure  in  colon  surgery  patients).  In  one  patient 
(0.09%) with ASA III to whom the ORS was not con-
sidered  appropriate,  minor  vomiting  occurred  after 
bag-valve-mask ventilation was performed. In female 
patients with malignant mammary tumor, 3 patients 
could not consume more than 500 mL of ORS because 
of taste preference and were treated with an intrave-
nous therapy instead. 
 
 
 
Table 3. Primary diseases of patients in the follow-up study 
Primary diseases  Number of 
patients 
Abnormality 
after induction 
of general an-
esthesia 
Malignant mammary tumors  237   
Malignant head and neck tumors  124   
Malignant tumors of the stomach  79   
Malignant tumors of the respira-
tory systems 
171   
Malignant tumors of the urinary 
and genital organs 
228  Vomiting, 1 
Malignant gynecological tumors  46   
Malignant bone and soft tissue 
tumors 
122   
Malignant tumors of the body 
surface 
27   
Other  44   
Total  1078  1 
Period of follow-up assessment: Between August 2007 and August 
2008. 
Average age (years): 60.2 (18 to 92). Sex ratio: 507 men and 674 
women. Int. J. Med. Sci. 2011, 8 
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Discussion 
The  ORT  used  in  the  present  study  has  been 
recognized to be safe and clinically effective for  the 
treatment of patients with cholera [9] and is consid-
ered to be an effective therapy for the treatment of 
dehydration and has attracted a great deal of interest 
in the United States and EU countries. Also, the use of 
oral  rehydration  solutions  is  recommended  by  the 
Centers  for  Disease  Control  and  Prevention  in  the 
United  States  for  the  treatment  of  patients  with 
mild-to-moderate  dehydration  [8].  The  OS-1,  which 
was used in the present study, is based on the concept 
of  ORT  as  recommended  by  the  World  Health  Or-
ganization [10], and its composition is based on the 
guidelines  of  the  American  Academy  of  Pediatrics 
[11].  In  Japan,  OS-1  has  been  approved  as  a  food 
(classified  as  a  food  for  special  dietary  use)  by  the 
Ministry of Health, Labour and Welfare of Japan, and 
has been shown to be effective for the provision of 
water and electrolytes in patients with dehydration as 
well as postoperative patients [12, 13]. Taking these 
advantages  into  consideration,  we  have  been  using 
ORT for the preoperative management of fluids and 
electrolytes in selected surgical patients in our hospi-
tal. 
With regard to the safety of ORT following in-
duction of anesthesia in the pilot study, there were no 
cases  of  aspiration  or  vomiting  associated  with  in-
duction of general anesthesia. A risk of aspiration has 
been reported to occur if the volume of gastric con-
tents exceeds 200 mL at the time of anesthesia induc-
tion [3], but no patients were found to have a volume 
of gastric contents greater than 200 mL in the present 
study.  With  regard  to  vital  signs,  changes  in  blood 
pressure (diastolic), pulse rate, and body temperature 
were significant before and at 1 and 2 h after treat-
ment, but systolic blood pressure showed an increase 
at 2 h after treatment. This increase was considered 
attributed to psychological pressure coupled with the 
time of entry to the operating room. 
With  regard  to  the  effectiveness  of  ORT,  the 
FENa was assessed as an index reflecting the effect on 
water supplementation. The FENa is a value that in-
dicates the percentage of sodium filtered by the renal 
glomerular capillaries and may be a sensitive index of 
the  renal  blood  flow  in  subjects  with  normal  renal 
function such as those enrolled in the present study. If 
the renal blood flow volume decreases in response to 
a reduction in circulating blood volume in dehydra-
tion,  the  FENa  value  falls  because  the  excretion  of 
sodium is reduced to promote sodium retention [14]. 
In the present study, because of the effect of preoper-
ative fasting from the evening before the day of sur-
gery, many patients showed low FENa values, which 
rose in response to rehydration by administration of 
the study solutions. These observations can be inter-
preted to mean that many patients were dehydrated 
in the morning of the day of surgery as a result of 
preoperative fasting but rehydrated by ORT. Follow-
ing  rehydration,  the  serum  chloride  and  potassium 
levels and hematocrit values showed no change, but 
the serum sodium level was decreased and glucose 
levels  were  increased.  Considering  that  the  urinary 
concentration of sodium did not change, the decrease 
in the serum sodium value is thought to be the result 
of dilution due to the effect of fluid supplementation 
by ORT. The blood glucose, which was lowered by 
fasting,  increased  with  glucose  intake  within  the 
normal  limit.  Consequently,  it  can  be  said  that  the 
results  of  this  study  confirm  the  effectiveness  and 
safety of ORT to some extent. 
Next, with regard to the questionnaire survey on 
patient  satisfaction  with  ORT  (the  survey  was  con-
ducted on the day after surgery), there were almost no 
complaints about dry mouth, feeling of hunger, and 
feeling of physical restriction before surgery, and it 
was  judged  that  patient  satisfaction  with  ORT  was 
high in all questionnaire items, as commented by the 
patients that they would prefer ORT to an intravenous 
therapy  the  next  time,  too.  However,  since  some 
complains were received in each questionnaire item 
(including the case of refusing to drink the fluid be-
cause of taste preference), the timing and volume of 
consumption  and  the  taste  and  temperature  of  the 
fluid should be further improved so that all patients 
can pleasantly drink for fluid and electrolyte replen-
ishment before surgery. 
In the follow-up study of 1078 patients, vomiting 
occurred in one patient (0.09%) following the induc-
tion of general anesthesia, and no aspiration was ob-
served.  This  patient,  who  was  receiving  an  oxygen 
therapy  at  home  for  chronic  obstructive  respiratory 
disease, was in grade III of the ASA physical status 
classification and, basically, was not the patient ap-
propriate for the ORT treatment, and it was probable 
that hyperinflation of the lung was always present in 
the patient,  compressing abdominal organs and de-
laying the movement of stomach content downwards. 
Although aspiration was not observed in this patient, 
aspiration has been reported to be fatal in the ASA III 
or  IV  grade  patients  [15].  Therefore,  when  we  use 
ORT,  it  seems  requisite  to  strictly  follow  specific 
standard. On the basis of these findings observed in 
the follow-up patients, ORT can be judged to be safe 
and effective when used before anesthesia induction, 
although  the  conditions  of  use  must  be  strictly  fol-
lowed. The eligibility standard for ORT at our hospi-Int. J. Med. Sci. 2011, 8 
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tal, which has been based on the results of this pro-
spective  observational  study  (pilot  and  follow-up 
study), is shown in Table 4, incorporated in our hos-
pital manuals and known to our hospital personnel. 
 Finally, it may be true that the duration of pre-
operative  fasting  is  still  long  in  Japan  as  compared 
with that in the United States and EU countries, and 
intravenous therapy is more likely to be used in Japan 
[2]. One reason lies in that there are no authorized 
national  guidelines  for  the  practice  of  preoperative 
fasting in this country, and some sort of guidelines 
should be established. Looking at the guidelines in the 
United  States  or  the  European  Union,  no  specific 
recommendations are given as to what kind of clear 
fluid  should  be  use.  The  oral  rehydration  solution 
used in the present study has been confirmed to be 
more-or-less  equal  to  the  intravenous  therapy  in 
terms of the effect on the supplementation of water, 
electrolytes,  and  carbohydrates  [8,  9].  We  conclude 
that ORT is a safe and effective therapy for the pre-
operative  fluid  and  electrolyte  management  of  se-
lected surgical patients. 
 
Table 4. Eligibility standard for oral rehydration therapy 
I. Patients eligible for oral rehydration therapy (receiving oral rehydration solution) 
1. Those who give an informed consent and have not been treated with prior medications 
2. Those with physical status classification I or II of ASA* 
II. Relative contraindications (patients may consume an oral rehydration solution if permitted by attending anesthesiologist) 
1. Those who are unable to understand instructions about the therapy (such as how to consume the oral rehydration solution). 
2. Those who had previously received surgery of upper gastrointestinal tract, liver, biliary tract, or pancreas 
3. Those who may have poor intestinal motility 
a) Severe obesity (BMI more than 28) 
b) Severe diabetes mellitus 
4. Those who are at high risk of aspiration 
a) Those who have abnormality of recurrent lanryngeal nerve due to neck-and-head diseases 
b) Those who may have difficulty in endotracheal intubation and mask ventilation 
c) Those who need prior medication of sedatives 
d) Those aged more than 80 years 
III. Absolute contraindications 
1. Those who are not permitted to take food by mouth 
2. Those who have gastrointestinal obstruction 
3. Those who have an increased cerebral pressure and consciousness disorder 
4. Those with physical status classification of ASA III or greater 
* American Society of Anesthesiologists. 
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